



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Chang, Xiao-Jia

Art Unit: 1641

Serial No: 10/615,343

Examiner: Grun, James Leslie


Filed: July 8, 2003

Attorney Docket No.: IGA-003.01

For: *Methods of Producing Antibodies for  
Diagnostics and Therapeutics*

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on October 17, 2005.

  
Shirine Darvish

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BASED ON  
INTERNATIONAL SEARCH REPORT**

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicant hereby makes of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of non-U.S. patent publications and documents (References C1-C5) are enclosed.

Applicant has listed dates of publication on the attached Form PTO-1449 for the cited documents based on information presently available to the undersigned. However, the listed publication dates should not be construed as indicating that the information in the cited documents was actually published or otherwise publicly available on the date indicated.

Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached Form PTO-1449.

This submission does not represent that a search has been made or that no better art exists. Nor does it constitute an admission that each or all of the listed documents are material or constitute "prior art." Further, if the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents. Moreover, the Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

It is believed that no fees are incurred by this submission. However, if any additional fees are due, the Commissioner is hereby authorized to charge any deficiencies or credit any overpayment to **Deposit Order Account No. 06-1448.**

Should there be any questions after reviewing this paper, the Examiner is invited to contact the undersigned at (617) 832-1000.

Respectfully submitted,

FOLEY HOAG LLP

By: 

Janann Y. Ali

Reg. No. 54,958

Agent for Applicant

Dated: October 17, 2005

**Customer No.: 25181**

Patent Group

Foley Hoag LLP

155 Seaport Boulevard

Boston, MA 02210-2600

Telephone: (617) 832-1000

Facsimile: (617) 832-7000

Form PTO-1449

**INFORMATION DISCLOSURE CITATION**  
**IN AN APPLICATION**  
*(Use several sheets if necessary)*
Docket Number (Optional)  
IGA-003.01Application Number  
10/615,343Applicant  
Chang, Xiao-JiaFiling Date  
July 8, 2003Group Art Unit  
1641
**U.S. PATENT DOCUMENTS**

EXAMINER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
	C1	03/012105 A	02/13/03	WIPO			

**OTHER DOCUMENTS**
*(Including Author, Title, Date, Pertinent Pages Etc.)*

	C2	Herrera-Gayol A. et al., "Adhesion proteins in the biology of breast cancer: contribution of CD44", Exp. and Mol. Pathology 1999 66(2):149-156					
	C3	Smith, K. et al. "Isolation and characterisation of vascular endothelial growth factor-165 specific scFv fragments by phage display", Int. J. of Oncology 2003 22(2):333-338					
	C4	Wittig B. et al., "Curative treatment of an experimentally induced colitis by a CD44 varian V7-specific antibody <sup>1</sup> ", J. Immunol. 1998 161(3):1069-1073					
	C5	International Search Report for PCT/US04/021812, mailed August 9, 2005					

EXAMINER

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.